Market currently homogenizing the stock prices of the 3 vaccine companies | NVAX Message Board Posts


NVAX   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message    Post Message    Post a Reply return to message boardtop of board
Msg  150497 of 165006  at  11/11/2021 11:40:33 AM  by

jamap


Market currently homogenizing the stock prices of the 3 vaccine companies

When MRNA's stock was trading in the mid $400s range towards the end of September, their total ;market cap value was worth about 10x higher than that of NVAX and today that difference is down to 7.2x, with the price difference down from about 77% in late September down to a manageable 33% today. In the case of BNTX the total market cap valuation difference has remained at about 4.4x greater than that of NVAX and the stock price gap has remained at around 37%. Once we start getting the approvals and begin to distribute vaccines to real people around the world, we should expect a significant improvement  in the SP and total market cap valuation of NVAX. Am hopeful that the company is able to close the valuation gap which would entail having a SP higher than MRNA and BNTX. The SP upside potential is very promising assuming no major dislocations with their global manufacturing operations.


     e-mail to a friend      printer-friendly     add to library      
|  
Recs: 2  
   Views: 0 []
Previous Message  Next Message    Post Message    Post a Reply return to message boardtop of board


Financial Market Data provided by
.
Loading...